Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) FCF Margin (2022 - 2025)

Taysha Gene Therapies' FCF Margin history spans 4 years, with the latest figure at 1035.75% for Q2 2025.

  • For Q2 2025, FCF Margin rose 91614.0% year-over-year to 1035.75%; the TTM value through Sep 2025 reached 1342.3%, down 50663.0%, while the annual FY2024 figure was 979.23%, 48161.0% down from the prior year.
  • FCF Margin for Q2 2025 was 1035.75% at Taysha Gene Therapies, down from 957.56% in the prior quarter.
  • Across five years, FCF Margin topped out at 6678.6% in Q2 2022 and bottomed at 2500.77% in Q4 2022.
  • The 4-year median for FCF Margin is 682.24% (2024), against an average of 194.91%.
  • The largest YoY upside for FCF Margin was 195795bps in 2023 against a maximum downside of -745856bps in 2023.
  • A 4-year view of FCF Margin shows it stood at 2500.77% in 2022, then surged by 78bps to 542.81% in 2023, then tumbled by -67bps to 905.34% in 2024, then dropped by -14bps to 1035.75% in 2025.
  • Per Business Quant, the three most recent readings for TSHA's FCF Margin are 1035.75% (Q2 2025), 957.56% (Q1 2025), and 905.34% (Q4 2024).